论文部分内容阅读
目的探讨行经皮冠状动脉介入术(percutaneous coronary intervention,PCI)治疗的冠心病患者的预后与糖化血红蛋白(glycosylated hemoglobin A1c,HbA1c)水平的相关性。方法 76例行PCI治疗的冠心病患者,35例HbA1c≥6.5%为观察组,41例HbA1c<6.5%为对照组。比较2组术后3、6、12个月预后不良事件发生率,并分析其与HbA1c水平的相关性。结果观察组中合并糖尿病24例,对照组合并糖尿病13例,2组比较差异有统计学意义(P<0.05);2组术后3、6、12个月不良事件发生情况以及PCI术后3个月总预后不良事件发生率比较差异无统计学意义(P>0.05);观察组PCI术后6、12个月总预后不良事件发生率(28.57%、42.58%)高于对照组(7.32%、14.63%)(P<0.05),且观察组PCI术后12个月总预后不良事件发生率(42.85%)高于术后3个月(14.29%)(P<0.05)。结论冠心病PCI预后与患者HbA1c水平有关,HbA1c水平较高者预后较差,控制HbA1c水平,尤其是对合并糖尿病的患者,对改善预后有重要意义。
Objective To investigate the relationship between the prognosis and the level of glycosylated hemoglobin A1c (HbA1c) in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). Methods 76 patients with coronary artery disease underwent PCI, 35 HbA1c≥6.5% as observation group and 41 HbA1c <6.5% as control group. The incidence of adverse events at 3, 6 and 12 months after operation was compared between the two groups and the correlation between HbA1c levels and the incidence of adverse events was analyzed. Results There were 24 cases with diabetes mellitus in the observation group and 13 cases in the control group with diabetes mellitus. The difference between the two groups was statistically significant (P <0.05). The incidence of adverse events at 3, 6 and 12 months after operation in both groups and 3 (P> 0.05). The incidence of adverse events (28.57%, 42.58%) in the observation group at 6 and 12 months after PCI was higher than that in the control group (7.32% , 14.63% respectively) (P <0.05). The incidence of adverse events (42.85%) in the observation group at 12 months after PCI was higher than that at 3 months (14.29%) after PCI (P <0.05). Conclusions The prognosis of patients with coronary heart disease is related to the level of HbA1c. The higher the level of HbA1c, the worse the prognosis. Controlling the level of HbA1c, especially in patients with diabetes mellitus, is of great significance in improving prognosis.